Logo

Caris Life Sciences Entered into a Multi-Year Strategic Option and License Agreement with Xencor for Novel XmAb Bispecific Antibodies to Treat Cancer

Share this
Caris Life Sciences Entered into a Multi-Year Strategic Option and License Agreement with Xencor for Novel XmAb Bispecific Antibodies to Treat Cancer

Caris Life Sciences Entered into a Multi-Year Strategic Option and License Agreement with Xencor for Novel XmAb Bispecific Antibodies to Treat Cancer

Shots:

  • Caris to receive an up front & will be eligible to receive ~$120M in license fees, discovery, development, regulatory & sales-based milestones along with royalty on net sales of each product commercialized by Xencor
  • Caris gets the rights for molecular profiling & companion diagnostics for drug candidates & will use its discovery platform to identify novel targets for bispecific Ab drug candidates. Xencor to get an exclusive option to research, develop & commercialize the products directed to ~3 targets
  • The collaboration will combine Caris' multi-omics target discovery engine with Xencor's XmAb engineering platform to manufacture bispecific Abs for the development of therapies to treat cancer

Ref: PR Newswire | Image: Caris Life Sciences 

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions